Abstract:Abstract The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most commonly in EGFR -mutant non-small cell lung cancer, secondary resistance mutations on the target kinase domain emerge to diminish the binding affinity of first- and second-generation inhibitors. Other alternative resistance mechanisms include activating complementary bypass pathways and phenotypic transformation. Sequential monotherapies promise to temporarily address the problem of acquired drug resistance, but evidently are limited by the tumor cells’ ability to adapt and evolve new resistance mechanisms to persist in the drug environment. Recent studies have nominated a model of drug resistance and tumor progression under targeted therapy as a result of a small subpopulation of cells being able to endure the drug (minimal residual disease cells) and eventually develop further mutations that allow them to regrow and become the dominant population in the therapy-resistant tumor. This subpopulation of cells appears to have developed through a subclonal event, resulting in driver mutations different from the driver mutation that is tumor-initiating in the most common ancestor. As such, an understanding of intratumoral heterogeneity—the driving force behind minimal residual disease—is vital for the identification of resistance drivers that results from branching evolution. Currently available methods allow for a more comprehensive and holistic analysis of tumor heterogeneity in that issues associated with spatial and temporal heterogeneity can now be properly addressed. This review provides some background regarding intratumoral heterogeneity and how it leads to incomplete molecular response to targeted therapies, and proposes the use of single-cell methods, sequential liquid biopsy, and multiregion sequencing to discover the link between intratumoral heterogeneity and early adaptive drug resistance. In summary, minimal residual disease as a result of intratumoral heterogeneity is the earliest form of acquired drug resistance. Emerging technologies such as liquid biopsy and single-cell methods allow for studying targetable drivers of minimal residual disease and contribute to preemptive combinatorial targeting of both drivers of the tumor and its minimal residual disease cells.

ecDNA within tumors: a new mechanism that drives tumor heterogeneity and drug resistance

Exploring the potential of extrachromosomal DNA as a novel oncogenic driver

Transcriptional immune suppression and up-regulation of double-stranded DNA damage and repair repertoires in ecDNA-containing tumors

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance

Pioneering insights of extrachromosomal DNA (ecDNA) generation, action and its implications for cancer therapy

Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review

Extrachromosomal DNA (ecDNA) in cancer: mechanisms, functions, and clinical implications

Extrachromosomal DNA formation enables tumor immune escape potentially through regulating antigen presentation gene expression

Intercellular extrachromosomal DNA copy number heterogeneity drives cancer cell state diversity

A narrative review of tumor heterogeneity and challenges to tumor drug therapy

Origins and impact of extrachromosomal DNA

Small ring has big potential: insights into extrachromosomal DNA in cancer

Intratumor Heterogeneity As an Opportunity for Drug Sensitivity Prediction and Biomarker Discovery.

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

Extrachromosomal Circular DNA: A New Target in Cancer

Exosomal Noncoding RNAs and Tumor Drug Resistance

The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity

Intratumor heterogeneity of breast cancer detected by epialleles shows association with hypoxic microenvironment